Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)
Epistemonikos ID: cc566f6ecd0c015f3df569318a9788751ea2dff5
First added on: May 15, 2024